前列腺立体定向体部放疗:毒性与剂量反应综述
美国医学物理学家协会工作组系统检索2001至2018年前列腺SBRT研究,纳入分析晚期泌尿、肠道或性毒性及生活质量的研究,并进行正常组织并发症概率建模。多数患者接受35-40 Gy、5次分割,严重毒性(≥3级)通常<3%,毒性受剂量学和非剂量学因素影响,建议了膀胱、尿道和直肠的剂量约束。
要点
- 前列腺SBRT总体耐受良好,≥3级严重毒性通常<3%。
- 多数研究采用35-40 Gy、5次分割,部分中心用4次。
- 建议约束:膀胱V(Rx Dose)Gy<5-10 cc,尿道Dmax<38-42 Gy,直肠Dmax<35-38 Gy。
核心结论
- 前列腺SBRT总体耐受良好,毒性决定因素包括剂量学因素和患者因素。
研究设计与样本
- 系统检索PubMed 2001-2018年前列腺SBRT研究,纳入分析晚期泌尿、肠道或性毒性及生活质量的研究,并对有详细剂量体积和结局数据的研究进行正常组织并发症概率建模。
主要发现
- 共纳入13项泌尿效应研究、6项肠道效应研究和4项性效应研究,多数患者为低中危前列腺癌,接受35-40 Gy。
- 多数患者接受5次分割,部分中心使用4次分割,终点异质包括医生评分毒性和患者报告生活质量。
- 大多数毒性为轻中度(如1-2级),严重毒性(如3级或更高)总体发生率通常<3%。
- 副作用与剂量学和非剂量学因素均相关。
关键数值与推荐
- 建议剂量约束包括膀胱V(Rx Dose)Gy<5-10 cc、尿道Dmax<38-42 Gy、直肠Dmax<35-38 Gy,但当前数据未提供明确的耐受剂量指导。
临床怎么用
- 临床可参考建议的膀胱、尿道和直肠剂量约束进行前列腺SBRT计划设计,同时关注患者因素对毒性的影响。
局限性
- 当前数据未提供明确的耐受剂量指导,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ultrahypofractionationed radiation therapy for prostate cancer is increasingly studied and adopted. The American Association of Physicists in Medicine Working Group on Biological Effects of Hypofractionated Radiotherapy therefore aimed to review studies examining toxicity and quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer and model its effect. METHODS AND MATERIALS: We performed a systematic PubMed search of prostate SBRT studies published between 2001 and 2018. Those that analyzed factors associated with late urinary, bowel, or sexual toxicity and/or quality of life were included and reviewed. Normal tissue complication probability modelling was performed on studies that contained detailed dose/volume and outcome data. RESULTS: We found 13 studies that examined urinary effects, 6 that examined bowel effects, and 4 that examined sexual effects. Most studies included patients with low-intermediate risk prostate cancer treated to 35-40 Gy. Most patients were treated with 5 fractions, with several centers using 4 fractions. Endpoints were heterogeneous and included both physician-scored toxicity and patient-reported quality of life. Most toxicities were mild-moderate (eg, grade 1-2) with a very low overall incidence of severe toxicity (eg, grade 3 or higher, usually <3%). Side effects were associated with both dosimetric and non-dosimetric factors. CONCLUSIONS: Prostate SBRT appears to be overall well tolerated, with determinants of toxicity that include dosimetric factors and patient factors. Suggested dose constraints include bladder V(Rx Dose)Gy <5-10 cc, urethra Dmax <38-42 Gy, and rectum Dmax <35-38 Gy, though current data do not offer firm guidance on tolerance doses. Several areas for future research are suggested.
引用
- Wang K, Mavroidis P, Royce TJ, et al. Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response. Int J Radiat Oncol Biol Phys. 2020. PMID: 33358229. doi:10.1016/j.ijrobp.2020.09.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。